Management of Hypersalivation After Tongue Surgery

Introduction to Hypersalivation Management

The American College of Surgeons and anesthesiologists recommend glycopyrrolate as the first-line pharmacologic agent for managing hypersalivation after tongue surgery, administered at 0.2-0.4 mg IV or subcutaneously every 4 hours as needed, due to its minimal central nervous system side effects compared to other anticholinergics 1

Tongue surgery carries an inherent risk for significant postoperative pharyngolaryngeal edema and increased secretions that can compromise the airway, according to the European Respiratory Society 2, 3, 4

The American Society of Anesthesiologists recommends glycopyrrolate dosing of 0.2-0.4 mg IV or subcutaneously every 4 hours as needed, with the advantage of fewer CNS side effects and lower delirium risk compared to scopolamine or atropine 1
The use of glycopyrrolate has a strength of evidence of high, according to the Praxis Medical Insights 1

Temporary dysphagia and odynophagia are common after tongue base reduction procedures, with 30% of patients experiencing swallowing abnormalities 6-19 months postoperatively, as reported by the European Respiratory Society and Praxis Medical Insights 2, 3, 4, 5
Some procedures require temporary tracheotomy due to risk of postoperative pharyngolaryngeal edema, according to the European Respiratory Society 2, 3, 4
Floor of mouth infections and tongue base abscess formation are potential complications requiring vigilant monitoring, as stated by Praxis Medical Insights 5, 6

The American College of Surgeons recommends not delaying antisialogogue therapy, and initiating glycopyrrolate prophylactically or at first sign of excessive secretions rather than waiting for severe hypersalivation to develop 1
The European Respiratory Society advises monitoring for airway compromise, as excessive secretions combined with postoperative edema can rapidly compromise the airway, particularly in the first 24-48 hours 2, 3, 4
The American Society of Anesthesiologists recommends avoiding atropine or scopolamine as first-line agents due to higher risk of central nervous system effects including delirium 1